# Trastuzumab

## Herceptin inj 440mg

| TAH Drug Code      | [**IHER**](https://www.tahsda.org.tw/drugs/hissearch.php?drug_code=IHER)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
|:-------------------|:------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Indications        | Treatment of metastatic breast cancer who have tumours that overexpress Human Epidermal Growth Factor Receptor 2 protein (HER2). As single agent or in combination with paclitaxel or docetaxel. Treatment of HER2 +ve early breast cancer patients (EBC) following surgery, chemotherapy (neoadjuvant or adjuvant)& radiotherapy (if applicable).                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
| Dosing             | [Adjuvant Treatment of HER2-Overexpressing Breast Cancer] Administer at either: initial dose of 4 mg/kg over 90 minute IV infusion, then 2 mg/kg over 30 minute IV infusion weekly for 52 weeks, or initial dose of 8 mg/kg over 90 minutes IV infusion, then 6 mg/kg over 30?90 minutes IV infusion every 3 weeks for 52 weeks. [Metastatic HER2-Overexpressing Breast Cancer] Initial dose of 4 mg/kg as a 90 minute IV infusion followed by subsequent weekly doses of 2 mg/kg as 30 minute IV infusions. [Metastatic HER2-overexpressing Gastric Cancer] Initial dose of 8 mg/kg over 90 minutes IV infusion, followed by 6 mg/kg over 30-90 minutes IV infusion every 3 weeks.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| Hepatic Impairment | Dose adjustment not necessary                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
| Renal Impairment   | Dose adjustment not necessary                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
| Contraindications  | Patients with known hypersensitivity to trastuzumab or to any other component of Herceptin                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
| Adverse Effects    | Abdominal pain, accidental injury, asthenia, back pain, chest pain, chills, fever, flu syndrome, headache, infection, neck pain, vasodilation, GI disturbances, peripheral edema, edema, arthralgia, myalgia, anxiety, depression, dizziness, insomnia, paresthesia, somnolence, asthma, cough increased, dyspnea, epistaxis, lung disorders, pleural effusion, pharyngitis, rhinitis, sinusitis, pruritus, rash. Cardiovascular: Edema (8% monotherapy ), Peripheral edema (5% to 10% ), Tachycardia (5% monotherapy ) Dermatologic: Rash (4% to 18% ) Gastrointestinal: Abdominal pain (2% to 22% ), Diarrhea (7% to 25% monotherapy; 1.6% grade 3/5 adjuvant therapy ), Loss of appetite (14% monotherapy ), Nausea (6% to 33% ), Vomiting (3.5% to 23% ) Hematologic: Anemia (4% ), Febrile neutropenia (23% adjuvant therapy ), Leukopenia (3% ), Neutropenia (32% grade 3/4; 2% grade 4/5 ) Immunologic: Infectious disease (20% monotherapy; 22% grade 2/5 adjuvant therapy ) Musculoskeletal: Backache (5% to 22% ), Myalgia (4% to 10% ) Neurologic: Asthenia (4.5% to 42% ), Dizziness (4% to 13% ), Headache (6% to 26% ), Insomnia (14% monotherapy; 3.7% grade 2/5 adjuvant therapy ) Respiratory: Cough (2% to 26% ), Dyspnea (3% to 22% ), Pharyngitis (12% monotherapy ), Rhinitis (2% to 14% ) Other: Fever (6% to 36% ) |
| Pregnancy          | Human Data Suggest Risk in 2nd and 3rd Trimesters                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
| Lactation          | No (Limited) Human Data - Potential Toxicity                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |

## HERCEPTIN inj 600mg/5mL

| TAH Drug Code      | [**IHER6**](https://www.tahsda.org.tw/drugs/hissearch.php?drug_code=IHER6)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
|:-------------------|:--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Indications        | Breast cancer, adjuvant treatment, breast cancer, metastatic, gastric cancer, metastatic.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
| Dosing             | 600 mg (600 mg trastuzumab and 10,000 units hyaluronidase) administered subcutaneously over approximately 2-5 minutes once every 3 weeks.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
| Hepatic Impairment | Dose adjustment not necessary                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
| Renal Impairment   | Dose adjustment not necessary                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
| Contraindications  | Hypersensitivity to trastuzumab, Chinese hamster ovary (CHO) cell proteins, or any component of the formulation.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
| Adverse Effects    | >10%: Cardiovascular: Decreased left ventricular ejection fraction (4% to 22%) Central nervous system: Pain (47%), chills (5% to 32%), headache (10% to 26%), insomnia (14%), dizziness (4% to 13%) Dermatologic: Skin rash (4% to 18%) Gastrointestinal: Nausea (6% to 33%), diarrhea (7% to 25%), vomiting (4% to 23%), abdominal pain (2% to 22%), anorexia (14%) Infection: Infection (20%) Neuromuscular & skeletal: Weakness (4% to 42%), back pain (5% to 22%) Respiratory: Cough (5% to 26%), dyspnea (3% to 22%), rhinitis (2% to 14%), pharyngitis (12%) Miscellaneous: Infusion related reaction (21% to 40%, chills and fever most common; severe: 1%), fever (6% to 36%) |
| Pregnancy          | Human Data Suggest Risk in 2nd and 3rd Trimesters                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
| Lactation          | No (Limited) Human Data - Potential Toxicity                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |

